Methods modulating immunoregulatory effect of stem cells

A technology of mesenchymal stem cells and cytokines, which is applied in the field of enhancing the immunosuppressive activity or immunostimulatory activity of mesenchymal stem cells, and can solve the problems of unclear basic mechanism in vivo

Active Publication Date: 2015-10-28
RUTGERS THE STATE UNIV
View PDF5 Cites 14 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] Fundamental in vivo mechanisms by which MSCs modulate immune responses, suppression or induction are far from clear

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods modulating immunoregulatory effect of stem cells
  • Methods modulating immunoregulatory effect of stem cells
  • Methods modulating immunoregulatory effect of stem cells

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0094] Materials and Methods

[0095] mice. Male C57BL / 6, C3H / HeJCr and F1 (C57BL / 6xC3H) mice aged 6-8 weeks were from the National Cancer Institute (Frederick, Md.). IFNγ-R1 - / - Mice and iNOS - / - Mice were from Jackson Laboratory (Bar Harbor, Me.). Mice were maintained in the Robert Wood Johnson Medical School Vivarium. In each experiment, animals were matched according to age and sex, and all experiments were approved by the Institutional Animal Care and Use Committee.

[0096] reagent. Recombinant mouse IFNγ and TNFα, IL-1α, IL-1β monoclonal antibodies against mouse TNFα, IL-1α, IL-1β and CCR5, FITC-conjugated anti-mouse CD11b and PE-conjugated anti-mouse antibodies F4 / 80 was from eBiosciences (La Jolla, Calif.). Antibodies against IL-10 and TGF-β and recombinant mouse M-CSF were from R&D Systems (Minneapolis, Minn.). Anti-IFNγ was from Harlan (Indianapolis, Ind.). Anti-CXCR3 was from Invitrogen (Carlsbad, Calif.). Indomethacin, 1-methyl-DL-tryptophan (1-MT) and N...

Embodiment 2

[0108] The immunosuppressive function of MSCs is induced by pro-inflammatory cytokines.

[0109] To identify underlying mechanisms, clones of mouse MSCs were employed. The stem cell properties of these clones are defined by their ability to differentiate into adipocytes or osteoblasts and their surface markers CD34; CD11b; CD11c; CD45; MHC class II; CD44 + ;Sca-1 + ; MHC class Il ow expression to limit. All results presented herein were replicated using at least three different MSC clones.

[0110] Since most of the reported studies of MSC-induced immunosuppression were based on their effects on T cell proliferation and cytokine production, the effect of MSCs on IL-2-driven proliferation of T cell blasts was first examined. fresh CD4 + T cell blasts are generated from splenocytes by activation with anti-CD3 followed by expansion with IL-2 for several days (Devadas et al. (2006) Immunity 25:237-247; Radvanyi et al. (1996) Cell Immunol. 170:260- 273). T cell blasts were a...

Embodiment 3

[0118] Nitric oxide is required for MSC-induced immunosuppression

[0119]To identify the mechanisms by which immunosuppression induced by cytokine-exposed MSCs is affected, the anti-CD3-activated splenocytes (1:20, MSC:splenocytes) co-cultured with MSCs in the TRANSWELL system were examined in various designs. reaction. When the two chambers of the pores were separated by a permeable membrane (0.4 μm pore membrane), MSCs had little effect on T cell proliferation, suggesting that membrane-associated proteins or other local acting factors are critical for T cell proliferation induced by cytokine-primed MSCs. Inhibition of cell proliferation is critical. Although it was recently reported (Sato et al. (2007) supra) that PGE-2, but not IDO, was required, PGE-2 was found not to be involved. Indeed, it was found that indomethacin (10 μM, a PGE-2 blocker), anti-IL-10 (20 μg / ml), anti-TGFβ (20 μg / ml) or 1-methyl-DL-tryptophan ( 1-MT, 1 mM, an IDO inhibitor) had no effect on MSC-ind...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention provides methods or kits with inflammatory cytokines to pretreat 1-ISCs to augment their immune modulatory effect, in prevention and treatment of various diseases such as multiple sclerosis, arthritis, lupus, sepsis, hepatitis, cirrhosis, Parkinson's disease, chronic infections, and GvHD. The present invention relates to novel methods for enhancing the immunosuppressive or the immune stimulatory activities of mesenchymal stem cells (JvfSCs).

Description

technical field [0001] The present invention relates to novel methods for enhancing the immunosuppressive or immunostimulatory activity of mesenchymal stem cells (MSCs). [0002] government interest [0003] This invention was made under grant numbers GM866889, DE014913, and DE019932 from the National Institutes of Health and a stem cell grant from the New Jersey Commission on Science and Technology (NJCST-2042-014- 84) with the support of the completion. Background technique [0004] Cell therapy includes the administration of living cells for any purpose, including the diagnosis or prevention of any disorder, such as regenerative medicine, transplantation, and even cancer. Stem cells are believed to have great potential in cell therapy. However, its effective use in the clinical setting has not been clear for various reasons. [0005] Stem cells have two distinct features that distinguish them from other types of cells. First, they are non-specialized and capable of l...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12N5/0775
CPCA61K35/28A61K38/191A61K38/2006A61K38/217A61K45/06A61K2035/122C12N5/0663C12N2500/05C12N2501/10C12N2501/2301C12N2501/2317C12N2501/24C12N2501/25C12N2502/1114A61P1/16A61P31/00A61P31/12A61P35/00A61P37/04A61P37/06A61P37/08A61P43/00A61P7/00A61K2300/00C07K14/525C07K14/52C07K14/545C07K14/50C07K14/56C07K14/57C12N5/0662
Inventor 时玉舫任光文张莉英
Owner RUTGERS THE STATE UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap